English
BIMM-SOL project (2016-2018)
The goal of this project is to commercialize processes for analyzing molecular microbial biomarkers in the qualitative biological diagnosis of soils.
About the project: https://librairie.ademe.fr/recherche-et-innovation/2272-bimm-sol.html
Funding:
DIAMA project (2016-2021)
The DIAMA project is assessing and validating the Deeplex® Myc-TB test in Africa and Europe. This rapid molecular test (based on mass sequencing) detects and genotypes mycobacteria and predicts antituberculosis drug resistance in Mycobacterium tuberculosis complex strains.
Partners:
- Centre National Hospitalier de Pneumo-Phtisiologie - Benin,
- Prins Leopold Instituut voor Tropische Geneeskunde - Belgium (Bruxelles),
- Université des Sciences, des Techniques et des Technologies de Bamako (USTTB) - Mali,
- London School of Hygiene and Tropical Medicine (LSHTM) - United Kingdom (London),
- Service de Pneumophtisiologie de l’Hôpital National Ignace Deen - Guinea,
- Jimma University - Ethiopia,
- Université Catholique de Louvain (UCL) - Belgium (Louvain),
- The Bamenda Center for Health Promotion and Research - Cameroun,
- Institute National of Research Biomedical of Zaire (INRB) - Congo,
- Damien Foundation - Belgium (Bruxelles),
- Rwanda Biomedical Center (RBC) - Rwanda,
- University Cheikh Anta Diop - Senegal,
- World Health Organization (WHO).
Funding:
FLU-MICROBIOT project (2015-2018)
The goal of this project is to understand the role of microbiotas and the gastrointestinal and respiratory tracts in influenza co-infections.
Partners:
-
- INSERM - France (Lille),
- CNRS - France (Lille),
- Université Lille 1 Sciences et Technologie - France (Lille),
- Institut Pasteur de Lille - France (Lille),
- Minas Gerais Federal University - Brasil.
Funding:
BioDISSPOL project (2015-2018)
Development of microbial biomarkers for the identification and monitoring of sites polluted by chlorinated solvents.
Partners:
- BRGM - France (Lesquin),
- Université de Strasbourg - France (Strasbourg).
Funding:
MICROTYPE project (2014-2018)
This project underpins the worldwide surveillance of infectious agents like Brucella (the bacterium responsible for brucellosis) via the development of typing kits and databases.
Partners:
Funding:
Our turnkey solutions to exploit the potential of metagenomics
You are looking for:
|
 |
Discover our turnkey solutions:
DNA & RNA extractionBenefit from our optimized, standardized and reproductible protocols for all types of initial matrix (including negative and positive controls). |
Microbial biomassEstimate the quantity of gDNA corresponding to the microbial community in your samples, by using complex standard curves that are appropriate for your field of interest (intestinal, cutaneous microbiota etc.). |
|
|
|
||
Metabiote®Use a standardized approach for the targeted analysis of ubiquitous genes (16S rRNA, ITS 1/2, 18S rRNA, etc.), in order to:
|
Shotgun metagenomicsGet an overview of the organisms present in your samples such as:
|
|
|
|
||
MetatranscriptomicsCharacterize changes in gene expression within microbial communities, in order to better understand their main functions and how they adapt to their environment. |
Bacterial countsDetermine or validate changes in the abundance of specific bacteria using qPCR. Ask for a feasability study on your specific target or benefit from our «ready-to-qPCR» assays. |
|
About us
GenoScreen is a French biotech company specialised in genomics and bioinformatics. We offer innovative services and solutions based on the characterization and exploitation of DNA/RNA molecules.
GenoScreen works on all kinds of genomes (Human, animal, plant and microbial) and delivers solutions for research groups from the private and public sectors.
Our microbial expertise continues to deepen since 2008, alongside the development of optimized and standardized, analytical protocols by our R&D team.
As the French leader in this sector, GenoScreen offers solutions that address your needs to characterize and understand microbiota.
Work with GenoScreen and benefit from:
|
 |
They used our services:
- Laura Di Lodovico et al, Anorexia nervosa and gut microbiota: A systematic review and quantitative synthesis of pooled microbiological data, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020 Sept; 110114
- Céline L. Pouille et al. Chicory root flour – A functional food with potential multiple health benefits evaluated in a mice model, Journal of Functional Foods, 2020 Nov; 74:104174
- Luen-Luen Li et al, Impacts of microplastics exposure on mussel (Mytilus edulis) gut microbiota, Science of The Total Environment, 2020 Nov; 745:141018
- Julia Mougin et al, Development of a mreB-targeted real-time PCR method for the quantitative detection of Vibrio harveyi in seawater and biofilm from aquaculture systems, Aquaculture, 2020 Aug; 525:735337
Ask for a quote
Subcategories
GenoScreen
Partners
GenoScreen develops its technologies and know-how in genomics within a dense, well-structured network of partners.
These collaborations co-fund ambitious research programs and jointly develop innovative technologies: an effective and agile strategy that opens up new opportunities for our staff.
Collaborative research - At the heart of international innovation in genomics
GenoScreen is a partner in collaborative research projects that bring together startups, multinationals and public-sector organizations. Our R&D teams provide their knowledge and expertise in the molecular microbiology of isolated agents and complex communities. This allowed our teams to develop our own projects for elaborating innovative products and services.
Our projects are designed to:
- Improve the diagnosis and management of acute/chronic diseases on humans and animals,
- Characterize and monitor microbial biodiversity, with applications in agronomy, agrifood and environment.
The common feature of these projects is the development of molecular tools for the characterization, monitoring and diagnosis of microbial communities. The key objective is to market simple analytical solutions and (ultimately) preventive, corrective or even therapeutic products based on microorganisms.